Etiology of common GI conditions
|
|
|
|
|
|
Updated guidelines for treatment of C. difficile infection
|
|
|
|
|
|
The most common signs and symptoms of Gastrointestinal disorders
|
|
|
|
|
|
New strategies and treatments for common GI disorders
|
|
|
|
|
|
Updated guidelines for the use of biologics in inflammatory bowel disease (IBD)
|
|
|
|
|
|
Therapeutic drug monitoring in IBD treatment
|
|
|
|
|
|
Managing GI complications of immunotherapy
|
|
|
|
|
|
Management of refractory Gastroesophageal reflux disease (GERD)
|
|
|
|
|
|
Improved management of (irritable bowel syndrome IBS)
|
|
|
|
|
|
Techniques to effectively control acute GI bleeding
|
|
|
|
|
|
Steps to ensure delivery of high-quality colonoscopic care
|
|
|
|
|
|
Hereditary GI Cancer Syndromes and Genetic Testing
|
|
|
|
|
|
Management of fatty liver disease
|
|
|
|
|
|
Best practices for treatment of hepatitis C
|
|
|
|
|
|
Immunotherapy strategies in various GI malignancies
|
|
|
|
|
|
Drug therapy versus dietary therapy in GI treatment
|
|
|
|
|
|
The stool microbiome (the science behind clinical applications)
|
|
|
|
|
|
Managing refractory pouchitis
|
|
|
|
|
|
Prevention of antibiotic associated diarrhea (AAD) based upon current clinical evidence
|
|
|
|
|
|
Prevention of C. difficile associated diarrhea (CDAD) based upon current clinical evidence
|
|
|
|
|
|
Recommendations/guidelines for the management of celiac disease
|
|
|
|
|
|
Recommendations/guidelines for the management of inflammatory bowel disease (ulcerative colitis and Crohn’s disease)
|
|
|
|
|
|
Pharmacotherapy for gastrointestinal disorders
|
|
|
|
|
|
Common Gastrointestinal Conditions in pregnancy
|
|
|
|
|
|
Common GI conditions in Pediatrics
|
|
|
|
|
|
Recommendations/guidelines for the management of constipation
|
|
|
|
|
|
Smoking and GI disorders
|
|
|
|
|
|
Helicobacter pylori (H. pylori) and GI disorders
|
|
|
|
|
|
Impact of COVID-19 on GI practice
|
|
|
|
|
|